Abstract
Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.
Claims
-
A method for the treatment of a patient with ocular hypertension or glaucoma, which comprises administering to said patient in an ophthalmic formulation a pharmaceutically effective amount of a compound that inhibits the enzyme EgLN-3, and wherein the compound is selected from the group consisting of:
wherein:
R is H, C1-6 straight chain or branched alkyl, phenyl, or benzyl, or CO2R forms a salt of formula CO2−M+, with M+ being Li+, Na+, K+, or NH4+; and
R1 is H, C(O)CH3, or C(O)C6H5.
-
The method of claim 1, wherein the compound is selected from the group consisting of:
wherein:
R is H, H, CH3, C2H5, or i-C3H7; and
R1 is H or C(O)CH3.
- The method of claim 1, wherein the compound is administered in an implant.
- The method of claim 1, wherein the compound is administered as an intraocular injection.
- The method of claim 1 wherein the compound is administered topically to the eye in a composition comprising a pharmaceutically acceptable carrier.
- The method of claim 5 wherein the pharmaceutically effective amount of the compound in the composition is from 0.001 to 2% (w/v).
- The method of claim 6 wherein the pharmaceutically effective amount is from 0.01 to 1% w/v).
- The method of claim 5, wherein the pharmaceutically acceptable carrier comprises one or more ingredients selected from the group consisting of surfactants; tonicity agents; buffers; preservatives; co-solvents; gelling agents, vehicles, water, penetration enhancers, and viscosity building agents.
-
The method of claim 1 wherein said administering further comprises administering said one or more compounds together with or separate from at least one glaucoma treatment agent selected from the group consisting of:
β-blockers, prostaglandin analogs, carbonic anhydrase inhibitors, α2 agonists, miotics, rho kinase inhibitors and neuroprotectants.
Owners (US)
-
Alcon Research Ltd
(Jan 01 2008)
Explore more patents:
-
Alcon Manufacturing Ltd
(Feb 20 2007)
Explore more patents:
Applicants
-
Alcon Res Ltd
Explore more patents:
Inventors
-
Klimko Peter G
Explore more patents:
-
Pang Iok-hou
Explore more patents:
IPC Classifications
-
A61K31/47
Explore more patents:
Download PDF
Document Preview
Document History
- Publication: Dec 1, 2009
-
Application:
Feb 27, 2007
US 67962907 A
-
Priority:
Feb 27, 2007
US 67962907 A
-
Priority:
Feb 27, 2006
US 77706506 P